GJB2 and breast cancer: Although our data are limited by the small sample size, they support additional studies of Cx26 and Cx46 to further refine outcome prediction for the intermediate groups as defined by currently used classification systems of pathological response to neoadjuvant chemotherapy in breast cancer.